请选择 进入手机版 | 继续访问电脑版
查看: 74|回复: 0

【YSA x Z-Park】构建精准医疗未来版图(Frontiers in Precision Med...

[复制链接]

参加活动: 0

组织活动: 632

643

主题

643

帖子

2778

积分

管理员

Rank: 9Rank: 9Rank: 9

积分
2778
发表于 2019-4-5 23:52:11 | 显示全部楼层 |阅读模式
活动类型:
讲座
活动时间:
7 天前 至 2019-4-18 07:30 PM 商定
活动地点:
1000 Massachusetts Ave, Cambridge, MA02138
已报名人数:
0

活动评分

0

 

0(投票)

  •     5分 0.0%
  •     4分 0.0%
  •     3分 0.0%
  •     2分 0.0%
  •     1分 0.0%

  • 活动查看
  • 活动相册
  • 已通过
本期的Frontiers系列的话题是精准医疗(Precision Medicine),YSA和Z-Park有幸邀请到精准医疗领域优秀的企业家来给大家分享构建精准医疗未来版图。

78fcee28be9b504.jpg

With dramatic decreases in cost andturn-around time, next-generation sequencing (NGS) has become a powerful tool for basic research and various clinical applications. From the study of disease mechanisms to the search for predictive biomarkers to the design of personalized cancer vaccines, NGS is increasingly employed in applications of precision medicine.

daaa1d1.jpg

Speakers:

Jeff Cheng, Ph.D.
Chief Scientific Officer at Novogene

09d1b018.jpg

Talk title: Leading Edge Next-Generation Sequencing and Bioinformatics Services

Jeff Cheng, PhD, is currently the Chief Scientific Officer and Global Head of Biopharmaceutical Services at Novogene Corporation, a global next-generation sequencing and bioinformatics provider.
Prior to joining Novogene, Jeff was the Biomarker Science Leader and China Site Head in the Department of Oncology Biomarker Development at Genentech and Roche Product Development in Asia Pacific. Before that, he was the Head of Scientific Liaison for Biomarker Research at Roche Pharmaceuticals in Shanghai and a Principal Investigator of In Vivo Oncology at BeiGene among other positions.

Jeff obtained his Bachelor’s degree in Chemical Engineering from Tsinghua University in Beijing, China. He then went to Rice University for his PhD in Chemical and Biomolecular Engineering which was followed by a post-doctoral research fellowship at Massachusetts General Hospital and Harvard Medical School. His research there was focused on vascular biology and tumor micro-environment.
Mark Driscoll, Ph.D.
Co-founder and CSO at Shoreline Biome

d9ac5c3.jpg

Mark’s talk will present data that the combination of lysis, PCR design, long readamplicon, and database are key to identifying microbial strains that influence human health.
Dr. Mark Driscoll has led and supported teams launching transformative new sequencing innovations globally since 2000, including teams at 454 Life Sciences that launched the GS20, GS FLX, and the GS Junior Next Generation Sequencing systems. Mark has experience leading the development of hardware, software, informatics and reagents supporting transformative NGS technology advancements.  As a co-founder and CSO of Shoreline Biome, Mark has been instrumental in the development of their high throughput DNA preparation and rRNA amplicon NGS kits, including the first all-in-one 16S-23S long read Amplicon kit and 16S-23S database, that, in combination with the PacBio sequencing system, enables differentiation of closely related bacterial strains using high-throughput, long read rRNA gene sequencing. Dr. Driscoll received his Ph.D. in Biochemistry from the University of Rochester.

About Novogene:

82f00acd684a2430abd36716f34f145e.jpg
As the world’s largest NGS service provider, Novogene offers research, pre-clinical and clinical scientists abroad array of sequencing and bioinformatics services, including whole genome and exome sequencing, targeted panel sequencing, RNA sequencing, single cell sequencing and microbiome sequencing, for a wide spectrum of sample types. To date, we have:
  • The largest sequencing capacity in the world with: 27-Illumina NovaSeq, 30-Illumina HiSeq X, 20-PacBio Sequels, 5 Thermo Fisher Ion S5XL, and more!
  • Completed nearly 20,000 projects
  • Sequenced 3,700,000 samples for more than 10,000 global customers
  • Analyzed more than 500,000 biological samples (in 2017 alone!)
  • Published over 1,850 customer research papers in top publications, like Nature and Science
  • Accumulated approximately 50 NGS-related patents


In addition, Novogene has developed and validated several clinical-grade oncology assays for precision medicine following strict quality control standards to ensure the highest data quality. These include:
  • NovoFocus™ NSCLC CDx – A CFDA-approved 26-gene companion diagnostic assay for patients with non-small cell lung cancer
  • NovoFocus™ PARPi CDx – An analytically validated 45-gene companion diagnostic assay for patients who may benefit from PARP inhibitor treatment
  • NovoPM™ - A ~500-gene comprehensive genomic profiling panel for solid tumors
  • NovoNeoantigen™ - A robust bioinformatics pipeline for cancer neo-antigens identification using whole exome sequencing and whole transcriptome sequencing data from paired tumor-normal samples


Novogene is fully committed to helping you meet your drug R&D goals with our state-of-the-art sequencing facilities, unparalleled scale, efficiency, quality, and price.

About Shoreline Biome:

Shoreline Biome is a start-up company witha passion for developing innovative discovery technologies for the microbiomeand bringing these products to market.

Shoreline Biome has created discovery tools that are advancing the leading edge of understanding how the human microbiome functions across the entire landscape of human health and disease. The initial products from Shoreline Biome, are the first DNA sequencing assays to comprehensively, rapidly, and inexpensively identify all members of the microbiome down to the subspecies or strain level. These results are achieved through our superior cell breaking technology and rational product design. Our companion analysis software enables straight forward identification and quantitation of all of the bacteria in microbiome samples.

Event location: 1000 Massachusetts Ave,Cambridge, MA 02138

Event time: Time: 5:30pm-7:30pm,Thursday, April-18-2019
(Pizza will be served)

Please scan the QR code to register:
de23.jpg
Thank you for the full sponsorship from Novogene!

焦点图显示:

到期时间:
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

推荐阅读 More>
广告位

Powered by Boston Web Power
技术支持:Boston Web Power

© 2008-2016 波士顿万家网

合作伙伴

返回顶部 返回列表